Group 1 - Precigen, Inc. has signed a credit facility agreement worth up to $125 million to support its commercialization efforts for PAPZIMEOS and expand into international markets [2][3][4] - The credit facility consists of two tranches: the first tranche of $100 million was funded at closing, while the second tranche of $25 million can be drawn at the company's discretion until March 21, 2027 [2][4] - The funding aims to bolster the company's position in the U.S. market and pursue pediatric and other HPV-related indications, indicating potential for near-term revenue growth [3][4] Group 2 - Precigen is a biopharmaceutical company focused on the discovery and clinical-stage development of gene and cell therapies targeting diseases in immuno-oncology, autoimmune disorders, and infectious diseases [5]